Tech Company Financing Transactions
Resolve Therapeutics Funding Round
Resolve Therapeutics, operating out of St. Petersburg, received $2 million from Easton Capital and New Science Ventures.
Transaction Overview
Company Name
Announced On
5/17/2011
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Series A
Investors
Easton Capital (John Friedman)
New Science Ventures (Somu Subramaniam)
Proceeds Purpose
We continue to make progress towards our goal of clinical proof-of-concept for our investigational lupus compound RSLV-125.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
721 1st Ave. N
St. Petersburg, FL 33701
USA
St. Petersburg, FL 33701
USA
Phone
Undisclosed
Website
Email Address
Overview
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-125, its novel targeted biologic therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Peter Kiener
Chief Executive Officer
James Posada
VP - Manufacturing
Raj Dua
Browse more venture capital transactions:
Prev: 5/17/2011: VGo Communications venture capital transaction
Next: 5/17/2011: Telcare venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs